Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-β

Journal of Immunology

Volumn 175, Issue 11, 2005, Pages 7568-7574

  Iversen, Ann Charlotte ^a,b   Norris, Paula S ^a   Ware, Carl F ^a   Benedict, Chris A ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOTOXIN; PERFORIN; TUMOR NECROSIS FACTOR;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; FIBROBLAST; GENE EXPRESSION; GENE INDUCTION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; INTERFERON PRODUCTION; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; VIRION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 28244439891     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.11.7568     Document Type: Article

References (50)

1. Sweet, C. 1999. The pathogenicity of cytoraegalovirus. FEMS Microbiol. Rev. 23: 457-482.
2. Biron. C. A., K. S. Byron, and J. L. Sullivan. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320: 1731-1735.
3. Jawahar, S., C. Moody, M. Chan, R. Finberg, R. Geha, and T. Chatila. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol 103: 408-413.
4. Bukowski. J. F., B. A. Woda, and R. M. Welsh. 1984. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J. Virol. 52: 119-128.
5. Johnsen, A.-C., J. Haux, B. Steinkjer. U. Nonstad, K. Egeberg. A. Sundan, A. Ashkenazi, and T. Espevik. 1999. Regulation of APO-2 ligand/TRAIL expression in NK cells: involvement in NK cell-mediated cytotoxicity. Cytokine 11 : 664-672.
6. Oshimi, Y.. S, Oda, Y, Honda, S. Nagata, and S. Miyazaki. 1996. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. J. Immunol. 157: 2909-2915.
7. Medvedev, A. E., A.-C. Johnsen, J. Haux, B. Steinkjer. K. Egeberg, D. H. Lynch, A. Sundan, and T. Espevik. 1997. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 9: 394-404.
8. Orange, J. S., B. Wang, C. Terhorst, and C. A. Biron. 1995. Requirement for natural killer cell-produced Interferon γ in defense against murine cytomegalo-virus infection and enhancement of this defense pathway by interleukin 12 administration. J. Exp. Med. 182: 1045-1056.
9. Loh, J., D. T. Chu, A. K. O'Guin, W. M. Yokoyama, and H. W. Virgin, IV. 2005. Natural killer cells utilize both perforin and γ Interferon to regulate murine cytomegalovirus infection in the spleen and liver. J. Virol, 79: 661-667.
10. Lanier, L. L. 2005. NK cell recognition. Annu. Rev. Immunol. 23: 225-274.
11. Lodoen, M. B., and L. L. Lanier. 2005. Viral modulation of NK cell immunity. Nat. Rev. Microbiol. 3: 59-69.
12. Tomasec, P., V. M. Braud, C. Rickards, M. B. Powell, B. P. McSharry, S. Gadola, V. Cerundolo, L. K. Borysiewicz, A. J. McMichael, and G. W. Wilkinson. 2000. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 287: 1031.
13. Wang, E. C., B. McSharry, C. Retiere, P. Tomasec, S. Williams, L. K. Borysiewicz. V. M. Braud. and G. W. Wilkinson. 2002. UL40-mediated NK evasion during productive infection with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 99: 7570-7575.
14. Rölle, A., M. Mousavi-Jazi, M. Eriksson. J. Odeberg, C. Söderberg-Nauclér. D. Cosman, K. Kärre, and C. Cerboni. 2003. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)I and ULBP2 is counteracted by the viral UL16 protein. J. Immunol, 171: 902-908.
15. Welte, S. A., C. Sinzger, S. Z. Lutz, H. Singh-Jasuja, K. L. Sampaio. U. Eknigk, H.-G. Rammensee, and A. Steinle. 2003. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 33: 194-203.
16. Tomasec. P., E. C. Wang, A. J. Davison, B. Vojtesek, M. Armstrong. C. Griffin, B, P. McSharry, R. J. Morris, S, Llewellyn-Lacey. C. Rickards, et al. 2005. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat. Immunol 6: 181-188.
17. Fletcher, J. M., H. G. Prentice, and J. E. Grundy. 1998. Natural killer cell lysis of cytomegalovirus (CMV)-infected cells correlates with virally induced changes in cell surface lymphocyte function-associated antigen-3 (LFA-3) expression and not with the CMV-induced down-regulation of cell surface class I HLA. J. Immunol. 161: 2365-2374.
18. Cerboni, C., M. Mousavi-Jazi, A. Linde, K. S̈derström. M. Brytting. B. Wahren, K. Kärre, and E. Carbone. 2000. Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J. Immunol 164: 4775-4782.
19. Locksley, R. M., N, Killeen, and M. J. Lenardo. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
20. Benedict, C. A. 2003. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev. 14: 349-357.
21. Goldmacher, V. S.. L. M. Bartle. A. Skaletskaya. C. A. Dionne, N. L. Kedersha, C. A. Vater, J. W. Han, R. J. Lutz, S. Watanabe, E. D. Cahir McFarland, et al. 1999. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc. Natl. Acad. Sci. USA 96: 12536-12541.
22. Benedict, C. A., T. A. Banks. L. Senderowicz, M. Ko, W. J. Britt, A. Angulo, P, Ghazal, and C. F. Ware. 2001. Lymphotoxins and cytomegalovirus cooperatively induce interferon-β, establishing host-virus détente. Immunity 15: 617-626.
23. Ware, C, F. 2005, Network communications: lymphotoxins, LIGHT, and TNF. Anna. Rev. Immunol. 23: 787-819.
24. Ware, C. F., P. D. Crowe. M. H. Grayson, M. J. Androlewicz, and J. L. Browning. 1992. Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J. Immunol. 149: 3881-3888.
25. + NK cells. J. Immunol. 148: 2429-2436.
26. Browning, J. L., I. Dougas, A. Ngam-ek, P. R. Bourdon, B. N. Ehrenfels, K. Miatkowski, M. Zafari, A. M. Yampaglia, P. Lawton, and W. Meier. 1995. Characterization of surface lymphotoxin forms: use of specific monoclonal antibodies and soluble receptors. J. Immunol. 154: 33-46.
27. Crowe, P. D., T. L, VanArsdale. B. N. Walter, K. M. Dahms, and C. F. Ware. 1994. Production of lymphotoxin (LTα) and a soluble dimeric form of its receptor using the baculovirus expression system. J. Immunol Methods 168: 79-89.
28. Rooney, I., K. Butrovich, and C. F. Ware. 2000. Expression of lymphotoxins and their receptor-Fc fusion proteins by baculovirus. Methods Enzymol. 322: 345-363.
29. Granger, S. W., K. D. Butrovich, P. Houshmand, W. R. Edwards, and C. F. Ware. 2001. Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J. Immunol. 167: 5122-5128.
30. Rooney, I. A., K. D. Butrovich, A. A. Glass, S. Borboroglu, C. A. Benedict, J. C. Whitbeck, G. H. Cohen, R. J. Eisenberg, and C. F. Ware. 2000. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275: 14307-14315.
31. Sanchez, V., P. Angeletii, J. Engler, and W. Britt. 1998. Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J. Virol. 72: 3321-3329.
32. Naume, B., U. Nonstad, B. Steinkjer, S. Funderud, E. Smeland, and T. Espevik. 1991. Immunomagnetic isolation of NK and LAK cells. J. Immunol. Methods 136: 1-9.
33. Gong, J. H., G. Maki, and H. G. Klingemann. 1994. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells, Leukemia 8: 652-658.
34. Kerry. J. A., M. A. Priddy, C. P. Kohler, T. L. Staley, D. Weber, T. R. Jones, and R. M. Stenberg. 1997. Translational regulation of the human cytomegalovirus pp28 (UL99) late gene. J. Virol. 71: 981-987.
35. Thanos, D., and T. Maniatis. 1995. Identification of the ReI family members required for virus induction of the human β interferon gene. Mol. Cell Biol. 15: 152-164.
36. Van Antwerp, D. J., S. J. Martin, T. Kafri, D. R. Green, and I. M. Verma, 1996. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789.
37. Borysiewicz, L. K.. B. Rodgers, S. Morris, S. Graham, and J. G. Sissons. 1985. Lysis of human cytomegalovirus infected fibroblasts by natural killer cells: demonstration of an interferon-independent component requiring expression of early viral proteins and characterization of effector cells. J. Immunol. 134: 2695-2701.
38. Carr, W. H., A. M. Little, E. Mocarski, and P. Parham. 2002. NK cell-mediated lysis of autologous HCMV-infected skin fibroblasts is highly variable among NK cell clones and polyclonal NK cell lines. Clin. Immunol. 105: 126-140.
39. Dokun, A. O., D. T. Chu, L. Yang, A. S. Bendelac, and W. M. Yokoyama. 2001. Analysis of in situ NK cell responses during viral infection. J Immunol. 167: 5286-5293.
40. + cells and murine cytomegalovirus infection: what happens in situ? J. Immunol. 166: 1796-1802.
41. von Albertini, M., C. Ferran, C. Brostjan, F. H, Bach, and D. J. Goodman. 1998. Membrane-associated lymphotoxin on natural killer cells activates endothelial cells via an NF-κB-dependent pathway. Transplantation 66: 1211-1219.
42. Nagashima, S., R. Mailliard, Y. Kashii, T. E. Reichert, R. B. Herberman, P. Robbins, and T. L. Whiteside. 1998. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 91 3850-3861.
43. Cha, T.-A., E. Tom, G. W. Kemble, G. M. Duke, E. S. Mocarski, and R. R. Spaete. 1996. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol. 70: 78-83.
44. Lucin, P., S. Jonjic, M. Messerle, B. Polic, H, Hengel, and U. H. Koszinowski. 1994. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-γ and tumour necrosis factor. J. Gen. Virol. 75(Pt. 1): 101-110.
45. Randolph Habecker, J., C. J. Beall, P. E. Kolattukudy, and D. D. Sedmak. 1997. Monocyte chemoattractant protein-1 binding by cytomegalovirus-infected endothelial cells. Transplant. Proc. 29: 807-808.
46. Torigoe, S., D. E. Campbell, and S. E. Start. 1997. Cytokines released by human peripheral blood mononuclear cells inhibit the production of early and late cytomegalovirus proteins. Microbiol. Immunol. 41: 403-413.
47. Miller, D. M., B. M. Rahill, J. M. Boss, M. D. Lairmore, J. E. Durbin, J. W. Waldman, and D. D. Sedmak. 1998. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J. Exp. Med. 187: 675-683.
48. Miller, D. M., Y. Zhang, B. M. Rahill, W. J. Waldman, and D. D. Sedman. 1999. Human cytomegalovirus inhibits IFN-α stimulated antiviral and immunoregulatory responses by blocking multiple levels of IFN-α signal transduction. J. Immunol. 162: 6107-6113.
49. Colonna, M., G. Trinchieri, and Y. J. Liu. 2004. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5: 1219-1226.
50. Schroder, K., P, J. Hertzog, T. Ravasi, and D. A. Hume. 2004. Interferon-γ: an overview of signals, mechanisms and functions. J. Leukocyte Biol 75: 163-189.